SCHEMBL13610358

SCHEMBL13610358

Fc1ccc(CSSSc2ncccn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 2/20 0.42
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
TERT O14746 1/20 0.38
ATM Q13315 1/20 0.38
PKM P14618 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
IDO1 P14902 2/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11820131 0.79 HSD17B10 (0.52) MAPK1HSD17B10NPC1RAB9ASMN1; SMN2
SCHEMBL13610310 0.79 NPC1 (0.49) MAPK1HSD17B10NPC1RAB9ASMN1; SMN2
SCHEMBL13610379 0.79 EPHX1 (0.40) MAPK1HSD17B10NPC1RAB9ATDP1
SCHEMBL13610341 0.77 RAB9A (0.45) NPC1RAB9ASMN1; SMN2NPSR1TP53
SCHEMBL1740610 0.77 IDO1 (0.50) NPC1RAB9ANPSR1TP53HTT
SCHEMBL13610362 0.77 RAB9A (0.48) MAPK1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL13610361 0.73 PDK1 (0.58) NPC1RAB9ASMN1; SMN2NPSR1TP53
SCHEMBL13610460 0.72 ALDH1A1 (0.48) MAPK1HSD17B10SMN1; SMN2PKMALDH1A1
SCHEMBL13610391 0.72 EPHX1 (0.44) RAB9AIDO1KDM4E
SCHEMBL576909 0.72 IDO1 (0.54) HSD17B10NPC1RAB9ANPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742635-B1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES INC (US) 2018-03-07 EP disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF TST, CTH, CBS MAPK1 4581/4885HSD17B10 2102/4885NPC1 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.